TMO Reports Today: Street Targets Repriced, Stock Follows

Thermo Fisher Scientific delivered its October 21 earnings this morning with the stock already up 3.7% on the week, the Street freshly repriced, and short interest too small to matter.

The analyst setup into the print was one of the more decisive re-ratings the stock has seen in a single month. Morgan Stanley lifted its target from $650 to $730 on October 13, keeping an Overweight rating, while TD Cowen moved from $675 to $760 the same day. Barclays had already raised from $650 to $750 a week earlier. Three target raises from firms carrying positive ratings in eight days pulled the consensus mean to $690.62, essentially in line with Tuesday's close of $687.37. The direction of travel is more telling than the gap: Morgan Stanley's target was $620 back in late July, and Barclays was at $625. The Street added roughly $100 to its view of fair value in three months. Not everyone moved. Piper Sandler holds a Neutral at $600 and RBC Capital sits at Sector Perform with a $580 target, both unchanged since late July, so there is a visible split between the firms that repriced ahead of the print and those that did not.

Positioning in the lending market is about as relaxed as it gets. Short interest at 1.39% of the free float is genuinely negligible, and the month-long trend is lower, down roughly 11% over the past 30 days. Borrow availability is essentially unlimited, with no constraint on new short positions for anyone who wanted to establish one. Cost-to-borrow has eased further to 0.36%, down 24% over the week, reinforcing that demand to borrow the stock is minimal. The options market has drifted back toward a slight put tilt, with the put/call ratio at 0.82 on Tuesday, but that reading is almost exactly in line with the 20-day average of 0.82 and carries a z-score of minus 0.19. Options traders, in other words, are neither pressing hedges nor piling into calls. The earlier bullish skew noted ahead of the print has faded back to neutral.

The factor profile gives the bulls more to work with than the bears. The forward earnings momentum score ranks in the 85th percentile on a 12-month year-over-year basis, and the short score of 30.5 sits in the 83rd percentile for benign short positioning. Wikipedia attention has spiked to a z-score of 2.5 against TMO's own 90-day history, well above the recent baseline, which likely reflects the earnings day itself driving retail traffic. The bear case centres on margin compression: adjusted EBIT margin has contracted roughly 830 basis points to 22.6% since 2021, and the gross margin is still running well below 2019 levels. The EV/EBITDA multiple at 21.5 and PE at 25.4 leave little room for a miss.

Among correlated peers this week, CRL was the standout mover, up 5.5% over five days, while DHR barely budged at plus 0.6%. MEDP and IQV both gained roughly 2% to 3%, broadly in line with TMO's own weekly performance, suggesting the sector tone was constructive rather than stock-specific.

The question the print now answers is whether the margin trajectory has stabilised enough to justify the targets that Barclays, Morgan Stanley and TD Cowen pencilled in before seeing the numbers.